Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Bristol Myers Squibb › Officer exercised or converted 20K BMY derivative securities Insider trades
Why it stands out Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Mar 10, 2026
Reporting period Not applicable
Filed with the SEC Mar 12, 2026 Officer Option exercise
Context Classification option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0001908769-26-000004
Filed / recorded
Mar 12, 2026, 8:19 PM UTC
Added to OQRO Oct 2, 2026, 12:27 PM UTC
Data quality Verified: identifiers matched exactly
Issuer BRISTOL MYERS SQUIBB CO
Reporting person Gregory Scott Meyers
Officer title EVP, Chief Digital & Tech Off.
Security Performance Shares
Table Derivative (Table II)
Transaction date Mar 10, 2026
Acquired / disposed Disposed (D)
Footnotes from the filing Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2026. Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award.
Around the same time Fund moves
78 tracked managers disclosed the same change for Q1 2026. From a 13F filed Apr 10, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Insider filing
Traded Apr 1 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Apr 1 · filed 1 day later
Routine share withholding; mechanical by default.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Oct 23, 2024 Congress Disclosed purchase of BMY — reported range $1,001 - $15,000 Apr 28, 2025 Congress Disclosed sale of BMY — reported range $1,001 - $15,000 Dec 18, 2025 Congress Disclosed sale of BMY — reported range $1,001 - $15,000 Dec 19, 2025 Congress Disclosed purchase of BMY — reported range $1,001 - $15,000 Feb 5, 2026 Company filing · Form 8-K · Results, Reg FD Reported its results, and shared information with investors What came next Mar 20, 2026 FDA FDA drug approval: Opdivo Mar 26, 2026 5% stake The Vanguard Group reported a passive stake (13G) Apr 1, 2026 Insider · 1 person Insiders: 2 sales (~$1.9M) Apr 29, 2026 5% stake Vanguard Capital Management reported a passive stake (13G) of 7.5%